CD4 count testing is perceived to be an affordable strategy to diagnose treatment failure on first-line antiretroviral therapy. We hypothesize that the superior accuracy of viral load (VL) testing will result in less patients being incorrectly switched to more expensive and toxic second-line regimens. Using data from a drug resistance cohort, we show that CD4 testing is approximately double the cost to make 1 correct regimen switch under certain diagnostic thresholds (CD4 = US $499 vs. VL = US $186 or CD4 = US $3031 vs. VL = US $1828). In line with World Health Organization guidelines, our findings show that VL testing can be both an accurate and cost-effective treatment monitoring strategy.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of acquired immune deficiency syndromes (1999)|
|State||Published - 2016|
Bibliographical notePublisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
- Antiretroviral therapy
- CD4 cell count
- Drug resistance
- South Africa
- Treatment failure
- Viral load
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, U.S. Gov't, Non-P.H.S.